Source:http://linkedlifedata.com/resource/pubmed/id/15002058
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2004-3-5
|
pubmed:abstractText |
The aim of this study was to evaluate the ability of the more sensitive second-generation TSH receptor (TRAb) assay to predict recurrent Graves' disease (GD) vs. remission depending on TRAb levels. 93 patients with active GD were included in the study. By using a cut-off limit of 1.0 IU/l, all 93 patients were positive for TRAb (median: 4.6 IU/l) at the time of their first visit (single point measurement in median 5.1 months after initial diagnosis). Subsequently, 33 patients went into remission and were euthyroid during follow-up (median follow-up: 21.7 months), whereas 60 patients did not go into remission or developed relapse over the following 24 months. Median TRAb levels in the group of remission were significantly (p < 0.0001) lower than TRAb values in the relapse group (2.1 compared to 8.6 IU/l). Applying ROC plot analysis to compare different TRAb thresholds, a cut-off of 10 IU/l was established. Here, the specificity for relapse was 97 % as only 1 of 29 patients with TRAb values above 10 IU/l went into remission during follow-up, whereas all other 28 patients developed a relapse (positive predictive value for relapse: 96.4 %). In contrast, TRAb values lower than 10 IU/l had no impact on the prediction of remission. In conclusion, our data clearly indicate that TRAb measurement is useful for identifying patients that will not benefit from long-term antithyroid drug treatment.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antithyroid Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Autoantibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Carbimazole,
http://linkedlifedata.com/resource/pubmed/chemical/Methimazole,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Thyrotropin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0018-5043
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
36
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
92-6
|
pubmed:dateRevised |
2009-2-19
|
pubmed:meshHeading |
pubmed-meshheading:15002058-Adolescent,
pubmed-meshheading:15002058-Adult,
pubmed-meshheading:15002058-Aged,
pubmed-meshheading:15002058-Antithyroid Agents,
pubmed-meshheading:15002058-Autoantibodies,
pubmed-meshheading:15002058-Carbimazole,
pubmed-meshheading:15002058-Female,
pubmed-meshheading:15002058-Graves Disease,
pubmed-meshheading:15002058-Humans,
pubmed-meshheading:15002058-Immunologic Techniques,
pubmed-meshheading:15002058-Male,
pubmed-meshheading:15002058-Methimazole,
pubmed-meshheading:15002058-Middle Aged,
pubmed-meshheading:15002058-Predictive Value of Tests,
pubmed-meshheading:15002058-ROC Curve,
pubmed-meshheading:15002058-Receptors, Thyrotropin,
pubmed-meshheading:15002058-Recurrence,
pubmed-meshheading:15002058-Remission Induction
|
pubmed:year |
2004
|
pubmed:articleTitle |
Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
|
pubmed:affiliation |
Department of Endocrinology, Heinrich-Heine-University Duesseldorf, Moorenstrasse 5, 40225 Duesseldorf, Germany. schottmt@uni-duesseldorf.de
|
pubmed:publicationType |
Journal Article,
Evaluation Studies
|